Advances in B-cell Lymphoma: From Diagnostics to Cure

Dear Colleagues, 

We are pleased to announce the call for submissions to a Special Issue of the journal Cancers, focusing on the topic of advances in B-cell lymphoma. Non-Hodgkin, B-cell lymphomas rank as the tenth most common cancer worldwide, accounting for >60% of all hematopoietic neoplasms. Over the past decade, significant advances have been made regarding the classification, prognostication and treatment of B-cell lymphomas, raising questions about how to best optimize the management of this heterogenous disease. 

This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in B-cell lymphoma, from its underlying pathology to innovative treatment strategies. We invite the submission of original research articles and reviews that cover various aspects of the management of B-cell lymphoma, including, but not limited to: 

1. Molecular and genetic profiling of B-cell lymphoma;
2. Novel biomarkers, prognostic markers and markers of minimal residual disease;
3. Insights into the tumor microenvironment and immune response;
4. Targeted therapies and immunotherapies for B-cell lymphoma;
5. Advances in cellular therapies. 

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians and experts in the field of hematopathology, lymphoma research and cellular therapy. 

By consolidating the latest research findings and clinical experiences, we aim to enhance our understanding of the newest advances in lymphoma diagnosis, classification, prognostication and management. We believe that your valuable contributions will significantly contribute to the success of this Special Issue. 

Should you have any questions, require further information or need any assistance, please do not hesitate to reach out to us. 

We look forward to receiving your valuable submissions. 

Prof. Dr. Leo I. Gordon
Dr. Megan E. Melody
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• B-cell lymphoma
• treatment
• molecular profiling
• immunotherapies
• cellular therapies